Research graph
References from Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
10.1016/j.ctrv.2014.06.012 · 2014 · External reference
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic Non–small-cell lung cancer in CheckMate 227
10.1200/jco.22.01503 · 2023 · External reference
Cancer immunotherapy: it's time to better predict patients' response
10.1038/s41416-021-01413-x · 2021 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
10.1158/2159-8290.cd-16-0828 · 2017 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
10.1016/s1470-2045(17)30074-8 · 2017 · External reference
Pseudoprogression and immune-related response in solid tumors
10.1200/jco.2015.61.6870 · 2015 · External reference
Global cancer imaging access: addressing barriers and harnessing innovations
10.1148/rycan.250019 · 2025 · External reference
Pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with nivolumab: a retrospective analysis
10.1016/j.clgc.2023.03.003 · 2023 · External reference
RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads
10.1186/s13244-024-01774-w · 2024 · External reference
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
10.20892/j.issn.2095-3941.2019.0144 · 2019 · External reference
Early assessment of lung cancer immunotherapy response via circulating tumor DNA
10.1158/1078-0432.ccr-17-1341 · 2018 · External reference
Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab
10.1158/1078-0432.ccr-18-0386 · 2018 · External reference
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
10.1038/s43018-020-0096-5 · 2020 · External reference
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
10.1158/2159-8290.cd-20-0047 · 2020 · External reference
Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy
10.1200/po.20.00321 · 2021 · External reference
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
10.1136/jitc-2020-001504 · 2021 · External reference
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
10.1038/s41591-023-02598-9 · 2023 · External reference
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer
10.1158/1078-0432.ccr-23-1469 · 2024 · External reference
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
10.1038/s41591-023-02226-6 · 2023 · External reference
Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study
10.1158/2767-9764.crc-25-0151 · 2025 · External reference
Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
10.1038/s41698-026-01287-3 · 2026 · External reference
Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
10.1038/s41598-019-53711-3 · 2019 · External reference
ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials
10.1158/1078-0432.ccr-24-3612 · 2025 · External reference
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
10.1038/s41416-023-02445-1 · 2023 · External reference
Detection of circulating tumor DNA in Early- and late-stage human malignancies
10.1126/scitranslmed.3007094 · 2014 · External reference
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference
10.1016/j.ijrobp.2006.04.029 · 2006 · External reference
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3
10.1200/jco.2015.64.2702 · 2016 · External reference
DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types
10.3390/cells9030624 · 2020 · External reference
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors
10.1158/2159-8290.cd-23-1060 · 2024 · External reference
Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
10.1038/s41598-025-90013-3 · 2025 · External reference
A clinician's handbook for using ctDNA throughout the patient journey
10.1186/s12943-022-01551-7 · 2022 · External reference
Brief report: methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC
10.1158/1557-3265.liqbiop24-b046 · 2024 · External reference
Absolute quantification of cell-free DNA for prenatal genetics and oncology
10.1016/j.tibtech.2024.12.003 · 2025 · External reference
Methylated ctDNA quantification: noninvasive approach to monitoring hepatocellular carcinoma burden
10.1097/xcs.0000000000000939 · 2024 · External reference
Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib
10.1016/j.jlb.2026.100467 · 2026 · External reference
Harmonizing cell-free DNA collection and processing practices through evidence-based guidance
10.1158/1078-0432.ccr-19-3015 · 2020 · External reference
Cell-free DNA, tumor molecular concordance, and clinical correlates of patients with cancer treated in a large community health care network
10.1016/j.jmoldx.2025.05.007 · 2025 · External reference
Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with Non–small-cell lung cancer treated with immune checkpoint inhibitors
10.1200/po.21.00372 · 2022 · External reference
Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies
2025 · External reference
Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents
2025 · External reference
RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis
10.1200/jco.18.01100 · 2019 · External reference
Pembrolizumab plus chemotherapy for squamous Non–small-cell lung cancer
10.1056/nejmoa1810865 · 2018 · External reference
Pembrolizumab plus chemotherapy in metastatic Non–small-cell lung cancer
10.1056/nejmoa1801005 · 2018 · External reference
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
10.1093/annonc/mdu239 · 2014 · External reference
Identification of factors affecting the success of next-generation sequencing testing in solid tumors
10.1093/ajcp/aqv023 · 2016 · External reference
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
10.1056/nejmoa1113205 · 2012 · External reference
Tracking the evolution of Non–small-cell lung cancer
10.1056/nejmoa1616288 · 2017 · External reference
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
10.1038/nature22364 · 2017 · External reference
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal
10.1016/j.cell.2018.03.057 · 2018 · External reference
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
10.1038/s41586-023-05776-4 · 2023 · External reference
The comings and goings of cell-free DNA: biological and clinical implications
10.1016/j.medj.2025.100926 · 2026 · External reference
